Search

Your search keyword '"Aning, Jonathan"' showing total 301 results
Start Over Author "Aning, Jonathan"
301 results on '"Aning, Jonathan"'

3. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Author

Einerhand, Sarah M. H., Black, Anna J., Zargar, Homayoun, Fairey, Adrian S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobson, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Kassouf, Wassim, Dall’Era, Marc A., Sridhar, Srikala S., McGrath, Jonathan S., Aning, Jonathan, Shariat, Shahrokh F., Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Daneshmand, Siamak, Zargar-Shoshtari, Kamran, Spiess, Philippe E., van Rhijn, Bas W. G., Black, Peter C., and Mertens, Laura S.

Published
2022
Full Text
View/download PDF

4. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

Author

Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed Musa, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kondža, Andraž, Barcelos, André, Galosi, Andrea Benedetto, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, de Jalón, Ángel García, Desai, Ankit, Czech, Anna Katarzyna, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Lal, Asim Ahmed, Yıldırım, Asıf, Voulgaris, Athanasios Marios, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, Chi-Fai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Plaza Alonso, Cristina, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Hrouda, David, Lau, David Hua Wu, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Canelon Castillo, Elba, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, MacLennan, Graeme, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Rios Pita, Hernado, Clarke, Holly, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Koo, Hui Fen, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomašković, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D., Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy Yuen-Chun, Iacovou, John, Kelly, John, Selph, John P., Aning, Jonathan, Deeks, Jon, Cobley, Jonathan, Olivier, Jonathan, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Gillams, Kathryn, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Antón-Juanilla, Marta, Rivero, Marta Viridiana Muñoz, Pirša, Matea, Tallè, Matteo, Crockett, Matthew, Liew, Matthew, Trail, Matthew, Peters, Max, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akalın, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al-Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Oteo Manjavacas, Pablo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C., Osei-Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L., Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P., Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Mohammud Inder, Shakeel, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Grzegorz Kata, Slawomir, Pinheiro Lopes, Sofia, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Shahzad, Yan, Sylvia, Lee, Taeweon, Uçar, Taha, Drake, Tamsin, Toma, Tarq, Cabañuz Plo, Teresa, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Tomaž, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çaşkurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Parejo Cortes, Victor, Capapé Poves, Victoria, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Fung Chin, Yew, Filtekin, Yigit, Chyn Phan, Yih, Ibrahim, Youssed, Glaser, Zachary A, Abiddin, Zainal Adwin, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli, Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Anbarasan, Thineskrishna, Mannas, Miles P., Marra, Giancarlo, Gómez Rivas, Juan, Marcq, Gautier, Assmus, Mark A., Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Boxall, Nicholas E., Downey, Alison P., Sukhu, Troy A., Chin, Yew-Fung, Green, James S.A., Goulao, Beatriz, Nielsen, Matthew, McGrath, John S., and Kasivisvanathan, Veeru

Published
2022
Full Text
View/download PDF

5. Prostate cancer–Exercise and Metformin Trial (Pre-EMpT): study protocol for a feasibility factorial randomized controlled trial in men with localised or locally advanced prostate cancer

Author

McGeagh, Lucy, Robles, Luke A., Persad, Raj, Rowe, Edward, Bahl, Amit, Aning, Jonathan, Koupparis, Anthony, Abrams, Paul, Perks, Claire, Holly, Jeffrey, Johnson, Lyndsey, Shiridzinomwa, Constance, Challapalli, Amarnath, Shingler, Ellie, Taylor, Hilary, Oxley, Jon, Sandu, Meda, Martin, Richard M., and Lane, J. Athene

Published
2022
Full Text
View/download PDF

6. National audit of patient reported experience of radical cystectomy for bladder cancer pathways.

Author

Kuppanda, Preksha, Hermans, Louisa, Uren, Alan, Cotterill, Nikki, Rowe, Edward, Narahari, Krishna, Dickinson, Andrew, Rigby, Jeannie, Aning, Jonathan, Calleja, Edward, Perry, Matthew, Abdulmajed, Mohamed, Dawam, Daben, Karanjia, Rustam, John, Joseph, Colquhoun, Alexandra, Mariappan, Paramananthan, Featherstone, Jon, Goodall, Philip, and Cooke, Pete

Published
2024
Full Text
View/download PDF

7. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

Author

D’Andrea, David, Black, Peter C., Zargar, Homayoun, Zargar-Shoshtari, Kamran, Soria, Francesco, Fairey, Adrian S., Mertens, Laura S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Campain, Nicholas J., Kassouf, Wassim, Dall’Era, Marc A., Seah, Jo-An, Ercole, Cesar E., Horenblas, Simon, Sridhar, Srikala S., McGrath, John S., Aning, Jonathan, Wright, Jonathan L., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Lotan, Yair, Grivas, Petros, Stephenson, Andrew J., Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Shariat, Shahrokh F.

Published
2021
Full Text
View/download PDF

9. Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus.

Author

Harding, Thomas A, Martin, Richard M, Merriel, Samuel WD, Jones, Robert, O'Sullivan, Joe M, Kirby, Mike, Olajide, Oluwabunmi, Norman, Alexander, Bhatt, Jaimin, Hulson, Oliver, Martins, Tanimola, Gnanapragasam, Vincent J, Aning, Jonathan, Burgess, Meg, Rosario, Derek J, Pashayan, Nora, Tesfai, Abel, Norori, Natalia, Rylance, Amy, and Seggie, Andrew

Subjects
EARLY detection of cancer, PROSTATE cancer patients, PRIMARY health care, ASYMPTOMATIC patients, PROSTATE-specific antigen
Abstract

Background: Screening is not recommended for prostate cancer in the UK. Asymptomatic men aged ≥50 years can request a prostate-specific antigen (PSA) test following counselling on potential harms and benefits. There are areas of clinical uncertainty among GPs, resulting in the content and quality of counselling varying. Aim: To produce a consensus that can influence guidelines for UK primary care on the optimal use of the PSA test in asymptomatic men for early prostate cancer detection. Design and setting: Prostate Cancer UK facilitated a RAND/UCLA consensus. Method: Statements covering five topics were developed with a subgroup of experts. A panel of 15 experts in prostate cancer scored (round one) statements on a scale of one (strongly disagree) to nine (strongly agree). Panellists met to discuss statements before rescoring (round two). A lived experience panel of seven men scored a subset of statements with outcomes fed into the main panel. Results: Of the initial 94 statements reviewed by the expert panel, a final 48/85 (56%) achieved consensus. In the absence of screening, there was consensus on proactive approaches to initiate discussions about the PSA test with men who were at higher-than-average risk. Conclusion: Improvements in the prostate cancer diagnostic pathway may have reduced some of the harms associated with PSA testing; however, several areas of uncertainty remain in relation to screening, including optimal PSA thresholds for referral and intervals for retesting. There is consensus on proactive approaches to testing in higher-than-average risk groups. This should prompt a review of current guidelines. [ABSTRACT FROM AUTHOR]

Published
2024

11. Real-time monitoring and feedback to improve shared decision-making for surgery (the ALPACA Study): protocol for a mixed-methods study to inform co-development of an inclusive intervention

Author

Hoffmann, Christin, primary, Avery, Kerry N L, additional, Macefield, Rhiannon C, additional, Snelgrove, Val, additional, Blazeby, Jane M, additional, Hopkins, Della, additional, Hickey, Shireen, additional, Cabral, Christie, additional, Hall, Jennifer, additional, Gibbison, Ben, additional, Rooshenas, Leila, additional, Williams, Adam, additional, Aning, Jonathan, additional, Bekker, Hilary L, additional, and McNair, Angus G K, additional

Published
2024
Full Text
View/download PDF

12. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Author

Zargar, Homayoun, Espiritu, Patrick, Fairey, Adrian, Mertens, Laura, Dinney, Colin, Mir, Maria, Krabbe, Laura-Maria, Cookson, Michael, Jacobsen, Niels-Erik, Gandhi, Nilay, Griffin, Joshua, Montgomery, Jeffrey, Vasdev, Nikhil, Yu, Evan, Youssef, David, Xylinas, Evanguelos, Campain, Nicholas, Kassouf, Wassim, DallEra, Marc, Seah, Jo-An, Ercole, Cesar, Horenblas, Simon, Sridhar, Srikala, McGrath, John, Aning, Jonathan, Shariat, Shahrokh, Wright, Jonathan, Thorpe, Andrew, Morgan, Todd, Holzbeierlein, Jeff, Bivalacqua, Trinity, North, Scott, Barocas, Daniel, Lotan, Yair, Garcia, Jorge, Stephenson, Andrew, Shah, Jay, van Rhijn, Bas, Daneshmand, Siamak, Spiess, Philippe, and Black, Peter

Subjects
Complete pathologic response, Cystectomy, GC, MVAC, Neoadjuvant chemotherapy, Partial pathologic response, Urothelial cancer, Aged, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Cisplatin, Cystectomy, Deoxycytidine, Doxorubicin, Europe, Female, Humans, Male, Methotrexate, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Staging, North America, Odds Ratio, Proportional Hazards Models, Retrospective Studies, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms, Vinblastine, Gemcitabine
Abstract

BACKGROUND: The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates (pT0) as high as 38%. However, because of the comparable efficacy with better tolerability of gemcitabine and cisplatin (GC) in patients with metastatic disease, GC has become the most commonly used regimen in the neoadjuvant setting. OBJECTIVE: We aimed to assess real-world pathologic response rates to NAC with different regimens in a large, multicenter cohort. DESIGN, SETTING, AND PARTICIPANTS: Data were collected retrospectively at 19 centers on patients with clinical cT2-4aN0M0 urothelial carcinoma of the bladder who received at least three cycles of NAC, followed by radical cystectomy (RC), between 2000 and 2013. INTERVENTION: NAC and RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was pathologic stage at cystectomy. Univariable and multivariable analyses were used to determine factors predictive of pT0N0 and ≤pT1N0 stages. RESULTS AND LIMITATIONS: Data were collected on 935 patients who met inclusion criteria. GC was used in the majority of the patients (n=602; 64.4%), followed by MVAC (n=183; 19.6%) and other regimens (n=144; 15.4%). The rates of pT0N0 and ≤pT1N0 pathologic response were 22.7% and 40.8%, respectively. The rate of pT0N0 disease for patients receiving GC was 23.9%, compared with 24.5% for MVAC (p=0.2). There was no difference between MVAC and GC in pT0N0 on multivariable analysis (odds ratio: 0.89 [95% confidence interval, 0.61-1.34]; p=0.6). CONCLUSIONS: Response rates to NAC were lower than those reported in prospective randomized trials, and we did not discern a difference between MVAC and GC. Without any evidence from randomized prospective trials, the best NAC regimen for invasive BCa remains to be determined. PATIENT SUMMARY: There was no apparent difference in the response rates to the two most common presurgical chemotherapy regimens for patients with bladder cancer.

Published
2015

13. 'Prehabilitation' checklist for men with prostate cancer starting androgen deprivation therapy.

Author

Payne, Heather, Bahl, Amit, Kirby, Mike, Rees, Jon, Aning, Jonathan, Das, Prantik, Cornford, Phil, and Bagnall, Pauline

Subjects
ANDROGEN deprivation therapy, PROSTATE cancer patients, MEDICAL personnel, PREHABILITATION, CANCER treatment
Abstract

Androgen deprivation therapy (ADT) plays an important, integral role in the treatment of prostate cancer; however, it is associated with multiple metabolic and other adverse effects. Making patients aware of these prior to starting ADT and assessing any specific risks during discussions is key to optimising outcomes. A brief checklist for health care professionals to use with patients, such as the one presented here, can aid discussions and facilitate signposting to appropriate specialist services without increasing workload. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy

Author

Ho, Matthew D., primary, Black, Anna J., additional, Zargar, Homayoun, additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Montgomery, Jeffrey S., additional, Yu, Evan Y., additional, Xylinas, Evanguelos, additional, Kassouf, Wassim, additional, Dall‘Era, Marc A., additional, Vasdev, Nikhil, additional, Sridhar, Srikala S., additional, McGrath, John S., additional, Aning, Jonathan, additional, Holzbeierlein, Jeff M., additional, Thorpe, Andrew C., additional, Shariat, Shahrokh F., additional, Wright, Jonathan L., additional, Morgan, Todd M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Grivas, Petros, additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, Van Rhijn, Bas W., additional, Daneshmand, Siamak, additional, Spiess, Philippe E., additional, and Black, Peter C., additional

Published
2023
Full Text
View/download PDF

15. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort

Author

Kirk, Peter S., Lotan, Yair, Zargar, Homayoun, Fairey, Adrian S., Dinney, Colin P., Mir, Maria C., Krabbe, Laura-Maria, Cookson, Michael S., Jacobson, Niels-Erik, Montgomery, Jeffrey S., Vasdev, Nikhil, Yu, Evan Y., Xylinas, Evanguelos, Kassouf, Wassim, Dall'Era, Marc A., Sridhar, Srikala S., McGrath, Jonathan S., Aning, Jonathan, Shariat, Shahrokh F., Thorpe, Andrew C., Morgan, Todd M., Holzbeierlein, Jeff M., Bivalacqua, Trinity J., North, Scott, Barocas, Daniel A., Grivas, Petros, Garcia, Jorge A., Stephenson, Andrew J., Shah, Jay B., Daneshmand, Siamak, Spiess, Philippe E., van Rhijn, Bas W. G., Mertens, Laura, Black, Peter, Wright, Jonathan L., and Urology

Subjects
Urology
Abstract

Purpose:While the presence of residual disease at the time of radical cystectomy for bladder cancer is an established prognostic indicator, controversy remains regarding the importance of maximal transurethral resection prior to neoadjuvant chemotherapy. We characterized the influence of maximal transurethral resection on pathological and survival outcomes using a large, multi-institutional cohort.Materials and Methods:We identified 785 patients from a multi-institutional cohort undergoing radical cystectomy for muscle-invasive bladder cancer after neoadjuvant chemotherapy. We employed bivariate comparisons and stratified multivariable models to quantify the effect of maximal transurethral resection on pathological findings at cystectomy and survival.Results:Of 785 patients, 579 (74%) underwent maximal transurethral resection. Incomplete transurethral resection was more frequent in patients with more advanced clinical tumor (cT) and nodal (cN) stage (P

Published
2023

16. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

Author

Fransen van de Putte, Elisabeth E., Horenblas, Simon, Potvin, Kylea R., Winquist, Eric, Seah, Jo-An, Sridhar, Srikala S., Jacobsen, Niels-Erik, Zargar-Shoshtari, Kamran, Holzbeierlein, Jeff M., Griffin, Joshua, Dinney, Colin, Krabbe, Laura-Maria, Lotan, Yair, Kovac, Evan, Ercole, Cesar E., Stephenson, Andrew J., Grivas, Petros, Cookson, Michael S., Baras, Alex, Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Campain, Nicholas J., McGrath, John S., Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Dall'Era, Marc A., Barocas, Daniel A., Fairey, Adrian S., Shariat, Shahrokh F., Aning, Jonathan, Zargar, Homayoun, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Bivalacqua, Trinity J., Spiess, Philippe E., Black, Peter C., and Kassouf, Wassim

Published
2018
Full Text
View/download PDF

17. Critique of fourier transform infrared microspectroscopy applications to prostate pathology diagnosis

Author

Aning, Jonathan and Stone, Nicholas

Subjects
615.84
Abstract

Prostate cancer is a biologically heterogenous disease with considerable variation in clinical aggressiveness. Gleason grade, the universally accepted method for classification of prostate cancer, is subjective and gives limited predictive information regarding prostate cancer progression. There is a clinical need for an objective, reliable tool to help pathologists improve current prostate tissue analysis methods and better assess the malignant potential of prostate tumours. Fourier Transform Infrared (FTIR) microspectroscopy is a powerful bioanalytical technique that uses infrared light to interrogate biological tissue. The studies detailed in this thesis examine the ability of FTIR combined with multivariate analysis to discriminate between benign, premalignant and malignant prostate pathology in snap frozen, paraffinated and deparaffinated tissue. Prostate tissue was collected during and after urological procedures performed between 2005 and 2008. The tissue was analysed utilising a bench top FTIR system in point and image mapping modes. The histology under interrogation was identified by a uro- pathologist. Multivariate analysis was applied to the spectral dataset obtained. FTIR performance was evaluated. FTIR was able to reproducibly discriminate between benign and malignant prostate tissue in a pilot study. Cross validated diagnostic algorithms, constructed from the spectral dataset in this experiment, achieved sensitivities and specificities of 95% and 89% respectively. FTIR analysis of transverse paraffinated and deparaffinated radical prostatectomy sections achieved good differentiation of the benign, premalignant and malignant pathology groups. However the performance of diagnostic algorithms constructed from this dataset under cross validation was poor. The work in this thesis illustrates the potential of FTIR to provide an objective method to assist the pathologist in the assessment of prostate samples. The limitations of the technique and directions for future work are presented.

Published
2010

21. PD39-07 CAN WE STOP DOING SYSTEMATIC BIOPSIES IN MEN WITH PIRADS/LIKERT 5 LESIONS ON MULTI PARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM A MULTICENTRE PROSPECTIVE DATASET OF OVER 800 PATIENTS

Author

Aning, Jonathan, primary, Andreou, Adrian, additional, Blaney, Liam, additional, Burn, Paul, additional, Oxley, Jon, additional, Mahoney, Sue, additional, Davies, Sarah-Jane, additional, Simmons, Lucy, additional, Trent, Neil, additional, Kopcke, Douglas, additional, Persad, Raj, additional, and Burns-Cox, Nick, additional

Published
2023
Full Text
View/download PDF

22. Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

Author

Bonnington, Sue, Bradshaw, Lynne, Cooper, Debbie, Elliott, Emma, Herbert, Pippa, Holding, Peter, Howson, Joanne, Jones, Mandy, Lennon, Teresa, Lyons, Norma, Moody, Hilary, Plumb, Claire, O'Sullivan, Tricia, Salter, Liz, Tidball, Sarah, Thompson, Pauline, Adam, Tonia, Askew, Sarah, Atkinson, Sharon, Baynes, Tim, Blaikie, Jan, Brain, Carole, Breen, Viv, Brunt, Sarah, Bryne, Sean, Bythem, Jo, Clarke, Jenny, Cloete, Jenny, Dark, Susan, Davis, Gill, De La Rue, Rachael, Denizot, Jane, Dewhurst, Elspeth, Dimes, Anna, Dixon, Nicola, Ebbs, Penny, Emmerson, Ingrid, Ferguson, Jill, Gadd, Ali, Geoghegan, Lisa, Grant, Alison, Grant, Collette, Gray, Catherine, Godfrey, Rosemary, Goodwin, Louise, Hall, Susie, Hart, Liz, Harvey, Andrew, Hoult, Chloe, Hawkins, Sarah, Holling, Sharon, Innes, Alastair, Kilner, Sue, Marshall, Fiona, Mellen, Louise, Moore, Andrea, Napier, Sally, Needham, Julie, Pearse, Kevin, Pisa, Anna, Rees, Mark, Richards, Elliw, Robson, Lindsay, Roxburgh, Janet, Samuel, Nikki, Sharkey, Irene, Slater, Michael, Smith, Donna, Taggart, Pippa, Taylor, Helen, Taylor, Vicky, Thomas, Ayesha, Tomkies, Briony, Trewick, Nicola, Ward, Claire, Walker, Christy, Williams, Ayesha, Woodhouse, Colin, Wyber, Elizabeth, Aning, Jonathan, Bollina, Prasad, Catto, Jim, Doble, Andrew, Doherty, Alan, Durkan, Garett, Gillatt, David, Hughes, Owen, Kocklebergh, Roger, Kouparis, Anthony, Kynaston, Howard, Leung, Hing, Mariappan, Param, McNeill, Alan, Paez, Edgar, Paul, Alan, Persad, Raj, Powell, Philip, Prescott, Stephen, Rosario, Derek, Rowe, Edward, Schwaibold, Hartwig, Tulloch, David, Wallace, Mike, Bahl, Amit, Benson, Richard, Beresford, Mark, Ferguson, Catherine, Graham, John, Herbert, Chris, Howard, Graham, James, Nick, Law, Alastair, Loughrey, Carmel, Mason, Malcolm, McClaren, Duncan, Patterson, Helen, Pedley, Ian, Robinson, Angus, Russell, Simon, Staffurth, John, Symonds, Paul, Thanvi, Narottam, Vasanthan, Subramaniam, Wilson, Paula, Appleby, Helen, Ash, Dominic, Aston, Dean, Bolton, Steven, Chalmers, Graham, Conway, John, Early, Nick, Geater, Tony, Goddall, Lynda, Heymann, Claire, Hicks, Deborah, Jones, Liza, Lamb, Susan, Lambert, Geoff, Lawrence, Gill, Lewis, Geraint, Lilley, John, MacLeod, Aileen, Massey, Pauline, McQueen, Alison, Moore, Rollo, Penketh, Lynda, Potterton, Janet, Roberts, Neil, Showler, Helen, Slade, Stephen, Steele, Alasdair, Swinscoe, James, Tiffany, Marie, Townley, John, Treeby, Jo, Wilkinson, Joyce, Williams, Lorraine, Wills, Lucy, Woodley, Owain, Yarrow, Sue, Bhattarai, Selina, Deshmukh, Neeta, Dormer, John, Fernando, Malee, Goepel, John, Griffiths, David, Grigor, Ken, Mayer, Nick, Oxley, Jon, Robinson, Mary, Varma, Murali, Warren, Anne, Brindle, Lucy, Davis, Michael, Dedman, Dan, Down, Elizabeth, Khazragui, Hanan, Metcalfe, Chris, Noble, Sian, Peters, Tim, Taylor, Hilary, Turner, Emma, Wade, Julia, Walsh, Eleanor, Baker, Susan, Bellis-Sheldon, Elizabeth, Bougard, Chantal, Bowtell, Joanne, Brewer, Catherine, Burton, Chris, Charlton, Jennie, Christoforou, Nicholas, Clark, Rebecca, Coull, Susan, Croker, Christine, Currer, Rosemary, Daisey, Claire, Delaney, Gill, Donohue, Rose, Drew, Jane, Farmer, Rebecca, Fry, Susan, Haddow, Jean, Hale, Alex, Halpin, Susan, Harris, Belle, Hattrick, Barbara, Holmes, Sharon, Hunt, Helen, Jackson, Vicky, Johnson, Donna, Le Butt, Mandy, Leworthy, Jo, Liddiatt, Tanya, Martin, Alex, Mauree, Jainee, Moore, Susan, Moulam, Gill, Mutch, Jackie, Parker, Kathleen, Pawsey, Christopher, Purdie, Michelle, Robson, Teresa, Smith, Lynne, Stenton, Carole, Steuart-Feilding, Tom, Sully, Chris, Sutton, Caroline, Torrington, Carol, Wilkins, Zoe, Williams, Sharon, Wilson, Andrea, Grant, Adrian, Roberts, Ian, Ashby, Deborah, Cowan, Richard, Fayers, Peter, Mellon, Killian, N'Dow, James, O'Brien, Tim, Sokhal, Michael, Baum, Michael, Adolfson, Jan, Albertsen, Peter, Dearnaley, David, Schroeder, Fritz, Roberts, Tracy, Zietman, Anthony, Mason, M.D., Moore, R., Jones, G., Lewis, G., Donovan, J.L., Neal, D.E., Hamdy, F.C., Lane, J.A., and Staffurth, J.N.

Published
2016
Full Text
View/download PDF

23. Study protocol for two pilot randomised controlled trials aimed at increasing physical activity using electrically assisted bicycles to enhance prostate or breast cancer survival

Author

Bourne, Jessica E, Foster, Charlie, Forte, Chloe, Aning, Jonathan, Potter, Shelley, Hart, Emma C, and Armstrong, Miranda E G

Subjects
ICEP
Abstract

BACKGROUND: In 2020, 1.4 and 2.3 million new cases of prostate cancer and breast cancer respectively were diagnosed globally. In the UK, prostate cancer is the most common male cancer, while breast cancer is the most common female cancer. Engaging in physical activity (PA) is a key component of treatment. However, rates of PA are low in these clinical populations. This paper describes the protocol of CRANK-P and CRANK-B, two pilot randomised controlled trials, involving an e-cycling intervention aimed at increasing PA in individuals with prostate cancer or breast cancer respectively.METHODS: These two trials are single-centre, stratified, parallel-group, two-arm randomised waitlist-controlled pilot trials in which forty individuals with prostate cancer (CRANK-P) and forty individuals with breast cancer (CRANK-B) will be randomly assigned, in a 1:1 allocation ratio, to an e-cycling intervention or waitlist control. The intervention consists of e-bike training with a certified cycle instructor, followed by the provision of an e-bike for 12 weeks. Following the intervention period, participants in the e-bike condition will be directed to community-based initiatives through which they can access an e-bike. Data will be collected at baseline (T0), immediately post intervention (T1) and at 3-month follow-up (T2). In addition, in the intervention group, data will be collected during the intervention and follow-up periods. Quantitative and qualitative methods will be used. The primary objectives are to determine effective recruitment strategies, establish recruitment and consent rates, adherence and retention in the study, and determine the feasibility and acceptability of the study procedures and intervention. The potential impact of the intervention on clinical, physiological and behavioural outcomes will be assessed to examine intervention promise. Data analyses will be descriptive.DISCUSSION: The findings from these trials will provide information on trial feasibility and highlight the potential of e-cycling as a strategy to positively impact the health and behaviour of individuals with prostate cancer and breast cancer. If appropriate, this information can be used to design and deliver a fully powered definitive trial.TRIAL REGISTRATION: CRANK-B: [ISRCTN39112034]. CRANK-P [ISRCTN42852156]. Registered [08/04/2022] https://www.isrctn.com .

Published
2023

24. Urinary Diversion

Author

Aning, Jonathan J., Hashim, Hashim, Klein, Eric A., Series editor, Wein, Alan J., editor, Andersson, Karl-Erik, editor, Drake, Marcus J., editor, and Dmochowski, Roger R., editor

Published
2014
Full Text
View/download PDF

25. MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool.

Author

Chau, Edwin M, Russell, Beth, Santaolalla, Aida, Van Hemelrijck, Mieke, McCracken, Stuart, Page, Toby, Liyanage, Sidath H, Aning, Jonathan, Gnanapragasam, Vincent J, and Acher, Peter

Abstract

Objective: To update and externally validate a magnetic resonance imaging (MRI)-based nomogram for predicting prostate biopsy outcomes with a multi-centre cohort. Materials and methods: Prospective data from five UK-based centres were analysed. All men were biopsy naïve. Those with missing data, no MRI, or prostate-specific antigen (PSA) > 30 ng/mL were excluded. Logistic regression analysis was used to confirm predictors of prostate cancer outcomes including MRI-PIRADS (Prostate Imaging Reporting and Data System) score, PSA density, and age. Clinically significant disease was defined as International Society of Urological Pathology (ISUP) Grade Group ⩾ 2 (Gleason grade ⩾ 7). Biopsy strategy included transrectal and transperineal approaches. Nomograms were produced using logistic regression analysis results. Results: A total of 506 men were included in the analysis with median age 66 (interquartile range (IQR) = 60–69). Median PSA was 6.6 ng/mL (IQR = 4.72–9.26). PIRADS ⩾ 3 was reported in 387 (76.4%). Grade Group ⩾ 2 detection was 227 (44.9%) and 318 (62.8%) for any cancer. Performance of the MRI-based nomogram was an area under curve (AUC) of 0.84 (95% confidence interval (CI) = 0.81–0.88) for Grade Group ⩾ 2% and 0.85 (95% CI = 0.82–0.88) for any prostate cancer. Conclusion: We present external validation of a novel MRI-based nomogram in a multi-centre UK-based cohort, showing good discrimination in identifying men at high risk of having clinically significant disease. These findings support this risk calculator use in the prostate biopsy decision-making process. Level of evidence: 2c [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. A 'real-world' standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016–2018.

Author

John, Joseph B, Pascoe, John, Fowler, Sarah, Walton, Thomas, Johnson, Mark, Aning, Jonathan, Challacombe, Benjamin, Bufacchi, Rory, Dickinson, Andrew J, and McGrath, John S

Abstract

Objective: To produce comprehensive and detailed benchmarking data allowing surgeons and patients to compare practice against, by using all recorded radical prostatectomies across a 3-year period in England. Patients and methods: The British Association of Urological Surgeons (BAUS) manages the radical prostatectomy (RP) Complex Operations Database. Surgical departments upload data which they can review and amend before lockdown and data cleansing. Analysis of 2016–2018 data held on the BAUS Complex Operations Database was performed for 21,973 patients undergoing RP in England, producing procedure-specific benchmarking data. General linear models were used to assess differences in patient selection between different operative modalities. Analysis involved assessment of case selection, operative decisions and outcomes, case volume and pathological outcomes. Results: Using national Hospital Episode Statistics, the BAUS RP dataset was estimated 91% complete. Median age was 65 and 96% were American Society of Anesthesiologists (ASA) Grades 1–2. Over 80% had RP performed in a high-volume centre (>100 annual RPs) and 88% had Gleason grade group (GGG) ⩾2 disease on biopsy. Robotic-assisted RP (RARP), laparoscopic RP (LRP) and open RP (ORP) were performed in 85%, 7.2% and 7.7% of cases, respectively. Patient and disease characteristics differed across surgical modalities. Transfusion rates were 0.14% in RARP, 0.38% in LRP and 1.8% in ORP. Increased positive surgical margin (PSM) rates were observed with increasing prostate-specific antigen (PSA), GGG and T-stage, with comparable PSM rates across surgical modalities. Lymph node dissection was performed more commonly in high-risk cases (cT3, PSA > 20, GGG ⩾ 4). Pathological upstaging was common. Median length of stay was 1, 2 and 3 days for RARP, LRP and ORP, respectively. ORP had Clavien–Dindo complications ⩾3 and unplanned hospital readmissions. Conclusion: This analysis has enabled the first set of UK national RP standards to be produced allowing procedure, patient and disease-specific national, centre and individual comparisons. The present degree of service centralisation, operative modalities, and specific aspects of surgical practice can be observed. Level of evidence: 2b [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. sj-docx-1-uro-10.1177_20514158231153251 – Supplemental material for Malignant upper urinary tract obstruction: A prospective evaluation of patients presenting as an emergency to urology and their long-term real-life outcomes

Author

Corkill, Joel, Hawthorne, Rachel, Westera, Jurjen, Collin, Neil, and Aning, Jonathan

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-1-uro-10.1177_20514158231153251 for Malignant upper urinary tract obstruction: A prospective evaluation of patients presenting as an emergency to urology and their long-term real-life outcomes by Joel Corkill, Rachel Hawthorne, Jurjen Westera, Neil Collin and Jonathan Aning in Journal of Clinical Urology

Published
2023
Full Text
View/download PDF

31. Additional file 1 of Study protocol for two pilot randomised controlled trials aimed at increasing physical activity using electrically assisted bicycles to enhance prostate or breast cancer survival

Author

Bourne, Jessica E., Foster, Charlie, Forte, Chloe, Aning, Jonathan, Potter, Shelley, Hart, Emma C., and Armstrong, Miranda E. G.

Abstract

Additional file 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*.

Published
2023
Full Text
View/download PDF

37. Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy

Author

Dinneen, Eoin, primary, Allen, Clare, additional, Strange, Tom, additional, Heffernan-Ho, Daniel, additional, Banjeglav, Jelena, additional, Lindsay, Jamie, additional, Mulligan, John-Patrick, additional, Briggs, Tim, additional, Nathan, Senthil, additional, Sridhar, Ashwin, additional, Grierson, Jack, additional, Haider, Aiman, additional, Panayi, Christos, additional, Patel, Dominic, additional, Freeman, Alex, additional, Aning, Jonathan, additional, Persad, Raj, additional, Ahmad, Imran, additional, Dutto, Lorenzo, additional, Oakley, Neil, additional, Ambrosi, Alessandro, additional, Parry, Tom, additional, Kasivisvanathan, Veeru, additional, Giganti, Francesco, additional, Shaw, Greg, additional, and Punwani, Shonit, additional

Published
2022
Full Text
View/download PDF

38. sj-docx-1-uro-10.1177_20514158211065949 ��� Supplemental material for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient���physician decision tool

Author

Chau, Edwin M, Russell, Beth, Santaolalla, Aida, Van Hemelrijck, Mieke, McCracken, Stuart, Page, Toby, Liyanage, Sidath H, Aning, Jonathan, Gnanapragasam, Vincent J, and Acher, Peter

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-1-uro-10.1177_20514158211065949 for MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient���physician decision tool by Edwin M Chau, Beth Russell, Aida Santaolalla, Mieke Van Hemelrijck, Stuart McCracken, Toby Page, Sidath H Liyanage, Jonathan Aning, Vincent J Gnanapragasam and Peter Acher in Journal of Clinical Urology

Published
2022
Full Text
View/download PDF

39. sj-docx-1-uro-10.1177_20514158211063964 ��� Supplemental material for A ���real-world��� standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016���2018

Author

John, Joseph B, Pascoe, John, Fowler, Sarah, Walton, Thomas, Johnson, Mark, Aning, Jonathan, Challacombe, Benjamin, Bufacchi, Rory, Dickinson, Andrew J, and McGrath, John S

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental material, sj-docx-1-uro-10.1177_20514158211063964 for A ���real-world��� standard for radical prostatectomy: Analysis of the British Association of Urological Surgeons Complex Operations Reports, 2016���2018 by Joseph B John, John Pascoe, Sarah Fowler, Thomas Walton, Mark Johnson, Jonathan Aning, Benjamin Challacombe, Rory Bufacchi, Andrew J Dickinson and John S McGrath in Journal of Clinical Urology

Published
2022
Full Text
View/download PDF

42. Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial

Author

Sooriakumaran, Prasanna, primary, Wilson, Caroline, additional, Rombach, Ines, additional, Hassanali, Neelam, additional, Aning, Jonathan, additional, D. Lamb, Alastair, additional, Cathcart, Paul, additional, Eden, Christopher, additional, Ahmad, Imran, additional, Rajan, Prabhakar, additional, Sridhar, Ashwin, additional, Bryant, Richard J., additional, Elhage, Oussama, additional, Cook, Jonathan, additional, Leung, Hing, additional, Soomro, Naeem, additional, Kelly, John, additional, Nathan, Senthil, additional, Donovan, Jenny L., additional, and Hamdy, Freddie C., additional

Published
2022
Full Text
View/download PDF

44. NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer.

Author

Dinneen, Eoin, primary, Grierson, Jack, additional, Magana, Ricardo Almeida, additional, Clow, Rosie, additional, Haider, Aiman, additional, Allen, Clare, additional, Heffernan-Ho, Daniel, additional, Freeman, Alex, additional, Briggs, Tim, additional, Nathan, Senthil, additional, Mallett, Susan, additional, Brew-Graves, Chris, additional, Muirhead, Nicola, additional, Williams, Norman, additional, Pizzo, Elena, additional, Persad, Raj, additional, Aning, Jonathan, additional, Johnson, Lyndsey, additional, Oxley, Jon, additional, Oakley, Neil, additional, Morgan, Susan, additional, Tahir, Fawzia, additional, Ahmad, Imran, additional, Dutto, Lorenzo, additional, Salmond, Jonathan, additional, Kelkar, Anand, additional, Kelly, John, additional, and Shaw, Greg, additional

Published
2022
Full Text
View/download PDF

46. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Lotan, Yair, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., Black, Peter, Fairey, Adrian S., Mertens, Laura S., Horenblas, Simon, Dinney, Colin P., Mir, Maria C., Ercole, Cesar E., Stephenson, Andrew J., Krabbe, Laura-Maria, Cookson, Michael S., Jacobsen, Niels-Erik, Barocas, Daniel A., Griffin, Joshua, Holzbeierlein, Jeff M., Montgomery, Jeffrey S., Morgan, Todd M., Vasdev, Nikhil, Thorpe, Andrew C., Aning, Jonathan, Yu, Evan Y., Wright, Jonathan L., Xylinas, Evanguelos, Campain, Nicholas J., Pourmalek, Farshad, McGrath, John S., Kassouf, Wassim, DallʼEra, Marc A., Seah, Jo-An, Sridhar, Srikala S., Sharma, Pranav, Shariat, Shahrokh F., North, Scott, Grivas, Petros, Gandhi, Nilay, and Bivalacqua, Trinity J.

Published
2016
Full Text
View/download PDF

48. Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial

Author

Thurtle, David, primary, Jenkins, Val, additional, Freeman, Alex, additional, Pearson, Mike, additional, Recchia, Gabriel, additional, Tamer, Priya, additional, Leonard, Kelly, additional, Pharoah, Paul, additional, Aning, Jonathan, additional, Madaan, Sanjeev, additional, Goh, Chee, additional, Hilman, Serena, additional, McCracken, Stuart, additional, Ilie, Petre Cristian, additional, Lazarowicz, Henry, additional, and Gnanapragasam, Vincent, additional

Published
2021
Full Text
View/download PDF

49. UK national bladder outlet obstruction surgery snapshot audit

Author

Aning, Jonathan J., primary, Calvert, Robert C., additional, Harding, Chris, additional, Fowler, Sarah, additional, Nitkunan, Tharani, additional, Lee, Su‐Min, additional, McGrath, John S., additional, Cresswell, Joanne, additional, Hagan, Patricia, additional, Hermans, Louisa, additional, and Dickinson, Andrew J., additional

Published
2021
Full Text
View/download PDF

50. MP72-15 THE INTERVAL BETWEEN DIAGNOSIS AND RADICAL CYSTECTOMY DOES NOT IMPACT THE OUTCOMES OF PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY

Author

Xylinas, Evanguelos, Zargar-Shoshtari, Kamran, Shah, Jay, Zargar, Homayoun, Fairey, Adrian, Mertens, Laura, Mir, Maria, Garcia, Jorge, Stephenson, Andrew, Krabbe, Laura-Maria, Cookson, Michael, Lotan, Yair, Jacobsen, Niels-Erik, Gandhi, Nilai, Griffin, Joshua, Montgomery, Jeffrey, Vasdev, Nikhil, Yu, Evan, Campain, Nicholas, Kassouf, Wassim, DallʼEra, Marc, Seah, Jo-An, Ercole, Cesar, Horenblas, Simon, Sridhar, Srikala, McGrath, Jonathan, Aning, Jonathan, Wright, Jonathan, Thorpe, Andrew, Morgan, Todd, Holzbeierlein, Jeff, Bivalacqua, Trinity, North, Scott, Barocas, Daniel, Daneshmand, Siamak, Van Rhijn, Bass, Spiess, Philippe, Dinney, Colin, Black, Peter, and Shariat, Shahrokh

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results